FY2025 Earnings Forecast for EYPT Issued By Chardan Capital

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities researchers at Chardan Capital issued their FY2025 EPS estimates for EyePoint Pharmaceuticals in a research report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings of ($2.92) per share for the year. Chardan Capital has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

A number of other brokerages have also recently commented on EYPT. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price on the stock. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to MarketBeat, EyePoint Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Trading Down 2.5 %

Shares of NASDAQ EYPT opened at $5.91 on Thursday. The stock has a market cap of $406.19 million, a P/E ratio of -2.96 and a beta of 1.41. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $23.65. The stock has a 50 day moving average of $6.82 and a two-hundred day moving average of $8.24.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of EyePoint Pharmaceuticals by 3.2% during the fourth quarter. Wellington Management Group LLP now owns 177,316 shares of the company’s stock worth $1,321,000 after acquiring an additional 5,552 shares during the period. California State Teachers Retirement System lifted its position in EyePoint Pharmaceuticals by 3.8% in the fourth quarter. California State Teachers Retirement System now owns 48,614 shares of the company’s stock valued at $362,000 after purchasing an additional 1,797 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in EyePoint Pharmaceuticals by 31.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 90,349 shares of the company’s stock worth $673,000 after purchasing an additional 21,719 shares during the period. Woodline Partners LP increased its position in EyePoint Pharmaceuticals by 25.4% during the 4th quarter. Woodline Partners LP now owns 501,724 shares of the company’s stock worth $3,738,000 after purchasing an additional 101,724 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 83.3% in the 4th quarter. Squarepoint Ops LLC now owns 40,514 shares of the company’s stock valued at $302,000 after buying an additional 18,416 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.